As Type 2 Diabetes Grows at Alarming Rates, Pharmaceutical Companies Will Face New Challenges and New Opportunities
FARMINGTON, Conn., Feb. 6, 2013 /PRNewswire-iReach/ -- Despite modern science's best efforts, the most common type of diabetes - Type 2 - is reaching epidemic levels across the world. The economic consequences of this growth are vast, involving not only the direct burden of managing the disease itself but also its common - often catastrophic - complications. Although more than 40 therapeutics are approved for type 2 diabetes, there are high levels of unmet need, creating opportunities for companies in the secondary and tertiary treatment segments that address such complications as cardiovascular disease, peripheral neuropathy, and blindness. These trends are of great concern, not only to the individuals affected, but also to governments and providers of health care.
Global Information (GII) provides the latest market insight and research on business opportunities within the diabetes market. Preview a selection of GII's most recently added reports below:
Global Markets for Diabetes Therapeutics and Diagnostics
The aim of this report is to provide detailed market, technology, and industry analyses to help readers quantify and qualify the market for drugs used in the treatment of diabetes and for devices and instruments used in the diagnosis and monitoring of diabetes.
This report discusses the implications of the above-mentioned trends in the context of the current size and growth of the diabetes market, discussed both in global terms and in terms of the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on merger and acquisition (M&A) activity. Five-year global sales forecasts are provided for main drug and device categories, and breakdowns are provided for several national markets.
An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/bc256185-global-markets-diabetes-therapeutics-diagnostics.html
Request free samples pages from Global Markets for Diabetes Therapeutics and Diagnostics -- Focus on Asia:http://www.giiresearch.com/report/bc256187-global-markets-diabetes-therapeutics-diagnostics.html
Request free samples pages from Global Markets for Diabetes Therapeutics and Diagnostics -- Focus on Europe: http://www.giiresearch.com/report/bc256188-global-markets-diabetes-therapeutics-diagnostics.html
Diabetes Therapeutics Market in India to 2018
With approximately 61.3 million diabetics in 2011, India presents a promising opportunity for pharmaceutical companies with anti-diabetic product portfolios. India, after China, is the second diabetes capital of the world. A growing patient population and increased demand for effective medication are offering both domestic and Multinational Companies (MNCs) promising opportunities.
MNCs rising interest in the emerging markets is indicated by the joint venture between Sun Pharma and Merck to bring new anti-diabetics to emerging markets, the USV-Novartis collaboration for the marketing of Galvus, the Lupin-Eli Lilly alliance for the marketing of insulin, and collaborations between Eli Lilly and Boehringer Ingelheim.
Through strategic consolidations such as these, MNCs are trying to expand their patient base by widening their reach in the domestic market. More aggressive marketing and a wider reach could potentially increase their market share and also develop a platform from which to ensure R&D success in terms of pipeline products. Strategic collaborations would help MNCs to market their products throughout India and overturn the competition in the established markets. They would also help domestic companies as having a MNC with sufficient resources in place on their side means strong sales forces and manufacturing capabilities. Given the large market and predicted double-digit growth rate, more strategic consolidations are expected to follow during the forecast period.
An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/gbi260640-diabetes-therapeutics-market-india-rapid-uptake.html
Diabetes Partnering 2007-2012
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
This data driven report contains over 500 links to online copies of actual diabetes deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors diabetes technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/wild243596-diabetes-partnering-2007-2012.html
For more market research highlights, technical research news and industry updates, please visit http://www.giiresearch.com/press/
About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.
SOURCE Global Information, Inc.